This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: AbCellera Biologics (ABCL) and Revolution Medicines (RVMD)

Tipranks - Tipranks - Tue May 5, 10:36AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AbCellera Biologics (ABCL) and Revolution Medicines (RVMD) with bullish sentiments.

Claim 55% Off TipRanks

AbCellera Biologics (ABCL)

In a report released today, Debanjana Chatterjee from JonesTrading maintained a Buy rating on AbCellera Biologics, with a price target of $11.00. The company’s shares closed last Monday at $4.62, close to its 52-week high of $4.75.

According to TipRanks.com, Chatterjee is a 5-star analyst with an average return of 50.8% and a 70.7% success rate. Chatterjee covers the Healthcare sector, focusing on stocks such as Contineum Therapeutics, Inc. Class A, Sagimet Biosciences, Inc. Class A, and Sionna Therapeutics, Inc. ;'>

AbCellera Biologics has an analyst consensus of Strong Buy, with a price target consensus of $8.33, representing an 87.4% upside. In a report issued on April 23, BMO Capital also maintained a Buy rating on the stock with a $7.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Revolution Medicines (RVMD)

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Revolution Medicines today and set a price target of $169.00. The company’s shares closed last Monday at $145.20.

According to TipRanks.com, Burns is a 5-star analyst with an average return of 19.9% and a 49.2% success rate. Burns covers the Healthcare sector, focusing on stocks such as BridgeBio Oncology Therapeutics, Black Diamond Therapeutics, and ArriVent BioPharma, Inc. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Revolution Medicines with a $172.41 average price target, a 22.1% upside from current levels. In a report issued on April 19, J.P. Morgan also maintained a Buy rating on the stock with a $175.00 price target.

Read More on ABCL:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).